A Study of SGN-MesoC2 in Advanced Solid Tumors

Stopped early · Phase 1

Conditions studied: Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Other Solid Tumors, Endometrial

In brief

This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Patients in this study must have cancer that has come back or did not get better with treatment. Patients must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called PF-08052666/SGN-MesoC2. PF-08052666/SGN-MesoC2 is a type of antibody-drug conjugate (ADC). ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will have 3 parts. Part A and Part B of the study will find out how much PF-08052666/SGN-MesoC2 should be given to participants. Part C will use the information from Parts A and B to see if PF-08052666/SGN-MesoC2 is safe and if it works to treat solid tumor cancers.

Key facts

Study ID

NCT06466187

Run by

Seagen, a wholly owned subsidiary of Pfizer

People needed

19

Starts

2024-08-02

Expected to finish

2026-05-27

Last updated by the study team

2026-07-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged 18 years or older.
• Histologically- or cytologically-confirmed metastatic or locally advanced unresectable platinum-resistant ovarian cancer, NSCLC, pancreatic ductal adenocarcinoma, endometrial cancer, colorectal cancer, or mesothelioma, who have relapsed or progressed following standard therapies, or for which no standard therapies are available.
• An Eastern Cooperative Oncology Group performance status score of 0 or 1.
• At least 1 measurable lesion at baseline based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).
• Archival tumor tissue or a fresh tumor biopsy during the screening period.
• Adequate hepatic, renal and bone marrow function.
• Participants must not have received more than 2 lines of cytotoxic systemic therapy in the metastatic setting (Parts B and C only).

You may not qualify if…

• Previously received or currently receiving any systemic anticancer therapy or focal radiotherapy within 4 weeks prior to the first dose of MesoC2 or within 2 weeks prior to the first dose of MesoC2 if the underlying disease had progressed on treatment.
• Prior anti-MSLN antibody or MSLN-directed ADC (Part C only).
• Unresolved toxicities from prior therapy greater than NCI CTCAE v5.0 grade 1 at the time of study treatment (except alopecia).
• Inadequate hepatic dysfunction, renal function, or hematologic abnormalities.
• Previously untreated brain metastases. Participants who received radiation or surgery for brain metastases are eligible if therapy was completed at least 4 weeks prior to study treatment initiation, and there was no evidence of central nervous system progression nor requirements for chronic corticosteroid therapy

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States
• The University of Alabama at Birmingham — Birmingham, Alabama, United States
• University of Alabama at Birmingham — Birmingham, Alabama, United States
• The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham — Birmingham, Alabama, United States
• The University of Kansas Clinical Research Center — Fairway, Kansas, United States
• The University of Kansas Hospital Cambridge North Tower A — Kansas City, Kansas, United States
• The University of Kansas Hospital — Kansas City, Kansas, United States
• The University of Kansas Medical Center Medical Office Building — Kansas City, Kansas, United States
• The University of Kansas Cancer Center - Indian Creek Campus — Overland Park, Kansas, United States
• The University of Kansas Cancer Center - Westwood — Westwood, Kansas, United States
• The University of Kansas Cancer Center, Investigational Drug Services — Westwood, Kansas, United States
• Atrium Health Wake Forest Baptist — Winston-Salem, North Carolina, United States
• Sarah Cannon Research Institute - Pharmacy — Nashville, Tennessee, United States
• SCRI Oncology Partners — Nashville, Tennessee, United States
• START San Antonio, LLC — San Antonio, Texas, United States
• START Mountain Region, LLC — West Valley City, Utah, United States
• University Health Network — Toronto, Ontario, Canada
• University Health Network, Princess Margaret Cancer Centre — Toronto, Ontario, Canada
• McGill University Health Centre — Montreal, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.